ProCE Banner Activity

NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma

Slideset Download
Conference Coverage
DA-EPOCH-R highly active in Burkitt lymphoma with reduced toxicity vs high-intensity treatment regimens.

Released: December 11, 2015

Expiration: December 09, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen